0001628280-26-007718
SEC filingVistaGen Therapeutics, Inc. reported its fiscal third quarter 2026 results with total revenues of $303K and a net loss of $18.9M for the period ending December 31, 2025. Operating expenses totaled $19.8M, driven primarily by $14.2M in research and development costs and $5.6M in general and administrative expenses. The company's operating loss stood at $19.5M. Interest income provided a partial offset of $647K. On the balance sheet, the company maintains a solid liquidity position with $47.4M in cash and cash equivalents and $14.4M in marketable securities, totaling $61.8M in liquid assets. Stockholders' equity was reported at $50.9M. Cash flow from operating activities used $32.0M during the quarter, while financing activities provided $31.3M, primarily through net proceeds of $30.6M from the sale of common stock under an Open Market Sale Agreement. The company continues to invest in its pipeline, with R&D representing the largest expense category.
For the fiscal third quarter ended December 31, 2025, VistaGen Therapeutics reported total revenues of $303K against total operating expenses of $19.8M, resulting in an operating loss of $19.5M. The net loss for the period was $18.9M, slightly better than the operating loss due to $647K in net interest income. The company reported a basic and diluted net loss per share of $0.00, with 42.2 million weighted average common shares outstanding. The comprehensive loss matched the net loss at $18.9M. This performance reflects the company's continued investment in research and development activities typical for a clinical-stage biopharmaceutical company.
The company reported minimal revenues of $303K for the quarter. As a clinical-stage biopharmaceutical company, VistaGen's revenue generation remains limited compared to its operating costs. The filing does not provide a detailed breakdown of revenue sources, geographic mix, or specific growth drivers. The revenue figure suggests early commercial or partnership activity, but the primary focus remains on pipeline development rather than commercial sales. No segment information was disclosed in the provided financial data.
VistaGen reported a negative operating margin of approximately 6435.6%, calculated as the operating loss of $19.5M divided by revenues of $303K. Research and development expenses constituted the largest cost component at $14.2M, representing 71.7% of total operating expenses. General and administrative expenses were $5.6M. The company continues to operate at a loss as it invests in developing its product candidates. Stock-based compensation of $3.1M was a significant non-cash expense included in operating costs.
The company reported cash and cash equivalents of $47.4M and marketable securities of $14.4M as of December 31, 2025, providing total liquid assets of approximately $61.8M. Total assets were $65.1M against total liabilities of $14.1M, resulting in stockholders' equity of $50.9M. Operating cash flow used $32.0M during the quarter. Financing activities provided $31.3M, primarily from $30.6M in net proceeds from common stock sales under an Open Market Sale Agreement. The accumulated deficit stands at $461.0M.
The filing indicates the company is actively raising capital to fund operations, evidenced by the $30.6M raised through the Open Market Sale Agreement during the quarter. With a cash burn of $32.0M from operations in Q3 and current liquid assets of $61.8M, the company appears to have sufficient runway for the near term, though continued financing will likely be necessary to advance clinical programs. No specific management guidance or strategic updates were provided in the financial data section.